Video: Targeted Therapies for Kidney Cancer

Six new targeted therapies have improved treatment for advanced, metastatic kidney cancer in recent years. These include anti-angiogenesis inhibitors, which destroy blood vessels that surround tumors, and mTOR inhibitors, which interfere with a process that fuels growth in cancer cells. As Memorial Sloan-Kettering medical oncologist Robert Motzer explains, these new drugs have significantly increased survival for many patients and have fewer side effects than chemotherapy. Memorial Sloan-Kettering’s multidisciplinary translational research team is working to develop new targeted therapies for patients who are not helped by currently available drugs.